EP0548238A1 - Non-aqueous liquid oral suspensions - Google Patents

Non-aqueous liquid oral suspensions

Info

Publication number
EP0548238A1
EP0548238A1 EP91917176A EP91917176A EP0548238A1 EP 0548238 A1 EP0548238 A1 EP 0548238A1 EP 91917176 A EP91917176 A EP 91917176A EP 91917176 A EP91917176 A EP 91917176A EP 0548238 A1 EP0548238 A1 EP 0548238A1
Authority
EP
European Patent Office
Prior art keywords
composition
cimetidine
oil
antagonist
oily vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91917176A
Other languages
German (de)
French (fr)
Inventor
Malcolm 8 Morris Way Foreman
Harvey Lee Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0548238A1 publication Critical patent/EP0548238A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the triglycerides of the C 8 -C 10 fatty acids of fractionated coconut oil which are available under the trade name of "Miglyol".
  • Miglyol is a triglyceride of capric and caprylic acids with glycerol.
  • the oils may also include sugar fatty acids known as "Olestras”.
  • the partially hydrogenated soybean oils are particularly preferred.
  • a species of this group of edible vegetable oils is commercially available under the trade name of "Durkex”. Most preferably, Durkex 25 is employed in the compositions of this invention.
  • Sugars such as, for example, mannitol, sorbitol,
  • compositions of this invention is within the skill of the pharmaceutical art except as specifically set forth herein.
  • the compositions are prepared following the conventional techniques well known to those skilled in the art involving variously mixing, suspending and dispersing the ingredients as appropriate to give the desired composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions liquides pharmaceutiquement élégantes et administrées par voie orale comprenant un antagoniste d'histamine H2 tel que la cimétidine dans un véhicule huileux comestible. Les compositions ont un goût très agréable et elles réduisent au minimum le goût amer associé à ces composés. On peut facultativement ajouter d'autres additifs pharmaceutiques bien connus en la matière.Pharmaceutically elegant liquid compositions administered orally comprising a histamine H2 antagonist such as cimetidine in an edible oily vehicle. The compositions have a very pleasant taste and they minimize the bitter taste associated with these compounds. Optionally, other pharmaceutical additives well known in the art can be added.

Description

NON-AQUEOUS LIQUID ORAL SUSPENSIONS
This invention relates to pharmaceutical compositions suitable for oral administration which comprise histamine H2-antagonists and result in an improved taste. Preferably, it relates to non-aqueous liquid oral suspensions which comprises cimetidine in an oily vehicle.
BACKGROUND OF THE INVENTION
Cimetidine is a histamine H2-antagonist which has been used for a number of years in the treatment of duodenal, gastric, stomal and recurrent ulceration. It has also been employed for reflux oesophagi tis and other conditions where reduction of gastric acid has been shown to be beneficial for example, persistent dyspeptic symptoms with or without ulceration. Cimetidine is absorbed almost exclusively in the small intestine where liquid compositions could be absorbed more quickly and efficiently than tablets.
It is known that cimetidine has a very bitter taste and the majority of the oral compositions containing cimetidine are considered unpalatable. The unpleasant taste associated with cimetidine is much more noticeable in liquid oral compositions, particularly in aqueous vehicles. This has presented a major problem in the preparation of liquid oral compositions. There has been a long standing need for an elegant, palatable liquid oral composition which will mask the unpleasant taste of cimetidine.
U.S. Patent 4,861,592 discloses aqueous buffered
cimetidine suspensions as an approach to overcome the
unpleasant taste of cimetidine. U.S. Patent 4,918,103 is representative of non-aqueous pharmaceutical vehicles employed to overcome stability problems associated with non steroidal anti-inflammatory drugs. U.S. Patents 4,639,367 and 4,752,465 disclose aerosol foams having the consistency of whipped cream employed as an alternative to liquid medicines having a bad taste. U.S. Patent 4,079,131 discloses anhydrous pharmaceutical vehicles employed to prepare permanent suspensions for water sensitive drugs.
DESCRIPTION OF THE INVENTION
According to the present invention there is provided a palatable non-aqueous liquid oral pharmaceutical suspension which comprises a histamine H2-antagonist, preferably
cimetidine, in an edible oily vehicle. By employing a one phase oily vehicle, it was unexpectedly discovered that the unpleasant taste of cimetidine associated with aqueous liquid vehicles was significantly minimized.
The oily vehicle employed in this invention may be, for example, an edible vegetable oil such as soybean oil, partially hydrogenated soybean oil, corn oil, sunflower oil, or peanut oil. The synthetic edible oils which are commercially
available and are equivalent to the vegetable oils may also be employed in this invention. For example, the triglycerides of the C8-C10 fatty acids of fractionated coconut oil which are available under the trade name of "Miglyol". Specifically, Miglyol is a triglyceride of capric and caprylic acids with glycerol. The oils may also include sugar fatty acids known as "Olestras". The partially hydrogenated soybean oils are particularly preferred. A species of this group of edible vegetable oils is commercially available under the trade name of "Durkex". Most preferably, Durkex 25 is employed in the compositions of this invention.
The above edible oils will be present in the non-aqueous pharmaceutical compositions of this invention in a range of from about 40% to about 90%, preferably from about 50 to about 80%.
The histamine H2-antagonist employed in the non-aqueous liquid suspensions of this invention may be for example, cimetidine, ranitidine, famotidine, nizatidine, etintidine, lupitidine, nifentidine, niperotidine, roxatidine, sufotidine, tuvatidine and zaltidine. Preferably, the H2-antagonist of this invention is cimetidine. It is well known that cimetidine can exist in at least five different polymorphic forms. Unless otherwise specified it is intended to include all polymorphs whether separated or mixtures thereof.
The H2-antagonist of this invention will be present in the non-aqueous suspension in a nontoxic but effective amount to produce systemically effective histamine H2-antagonistic activity. The suspension will contain from about 1.0% to about 12.0% W/V of the antagonist, preferably from about 4.0% to about 8.0% W/V.
The H2-antagonists are administered in conventional liquid dosage unit forms; preferab l y i n teaspoon quan t i t i e s . A teaspoon i s equ i va l en t to 5 ml . of the oral liquid composition. The active ingredient, for example, cimetidine will normally be administered in an amount of from about 50 mg. to about 600 mg. per dosage unit, advantageously from about 200 mg. to about 400 mg. per dosage unit. Equal doses within the ranges given above will be administered preferably from about one to about four times a day.
Other histamine H2-antagonists, for example, those noted above, can also be present in the compositions of this
invention in a nontoxic but pharmaceutically effective amount. The concentration will vary with the H2-antagonist employed and the unit dosage required. The compositions will contain the H2-antagonist in an amount within dosage unit ranges which are well known to the medical art.
To further enhance the basic compositions of this invention other pharmaceutically acceptable additives well known to the art may be optionally added. Exemplary of these additives would be flavoring agents such as peppermint, vanilla, licorice, cinnamon, chocolate, spearmint or a combination of flavors; sweetening agents selected from aspartame, sodium cyclamate, calcium cyclamate or sodium saccharin; preservatives such as, for example, methylparaben, propyl paraben, butylparaben, benzoic acid and sorbic acid; emulsifying and surface active agents selected from nontoxic anionics such as sodium lauryl sulfate, cationics such as benzalkonium chloride or a non-ionic agent such as
polyoxyethylene sorbitan monopalmi tate (Tween 40), sorbitan fatty acid esters, such as, sorbitan monopalmi tate (Span 40) and natural emulsifiers selected from acacia, gelatin lecithin and cholesterol; antioxidants selected from butylated
hydroxyanisole, butylated hydroxytoluene or tertiary
butylhydroquinone; and thickening agents such as silicon dioxide (Syloid) or colloidal silicon dioxide (Cab-O-Sil).
These thickening agents may be present in an amount of from about 0.1% to about 5.0% of the composition.
Sugars such as, for example, mannitol, sorbitol,
confectioners sugar, lactose, fructose and glucose may be employed as both thickening and sweetening agents. The sugars may be present in the nonaqueous compositions of this invention in an amount of from about 10% to about 40%.
The selection and amounts of the above pharmaceutically acceptable additives and their use in the nonaqueous
compositions of this invention is within the skill of the pharmaceutical art except as specifically set forth herein. The compositions are prepared following the conventional techniques well known to those skilled in the art involving variously mixing, suspending and dispersing the ingredients as appropriate to give the desired composition.
The invention is further illustrated by the following examples which are not intended to be limited in scope.
Example 1
Ingredient % W/V
Cimetidine 4 .0
Confectioners Sugar NF 12X 25 .0
Mannitol 10 .0
Cab-O-Sil 0. 2
Propyl paraben 0. 1
Tertiary Butyl hydroqui none 0 .02
Vanilla Flavor 0. 5
Peppermint Flavor 0. 5
Partially Hydrogenated
Soybean Oil (Durkex 25) q.s. 100. 0 ml .
50 ml. of Durkex 25 was placed in a propeller mixer and the propylparaben was dissolved in the oil. The flavors and butylhydroquinone were then added to the solution followed by the other ingredients with moderate mixing until the mixture was smooth and homogenous. The remaining Durkex was added with continued moderate mixing. The mixture was removed from the mixer and homogenized to a smooth consistency.
The formulations listed below were prepared following the procedure of Example 1.
Example 2
Ingredients % W/V
Cimetidine 8 .0
Mannitol 40 .0
Aspartame 0. 1
Cab-O-Sil 0 .2
Propylparaben 0. 1
Tertiary Butyl hydroqui none 0. 02
Vanilla 0. 5
Peppermint 0. 5
Durkex 25 q.s. 100. 0 m l .

Claims

What is claimed is:
1. A non-aqueous liquid pharmaceutical composition for oral administration comprising a nontoxic effective amount of a histamine H2-antagonist and an edible oily vehicle.
2. The composition according to Claim 1 wherein the H2-antagonist is cimetidine.
3. The composition of Claim 2 wherein the cimetidine is present in an amount of from about 1.0% to about 12.0% W/V of the composition.
4. The composition of Claim 2 wherein the edible oily vehicle comprises soybean oil, partially hydrogenated soybean oil, corn oil, sunflower oil, peanut oil, coconut oil, or fractionated coconut oil.
5. The composition of Claim 4 wherein the oily vehicle is partially hydrogenated soybean oil.
6. The composition of Claim 4 wherein the oily vehicle is present in an amount of from about 40% to about 90% W/V of the composition.
7. The composition of Claim 4 wherein the composition includes sugars selected from the group consisting of mannitol, sorbitol, lactose, fructose or confectioners sugar.
8. The composition of Claim 7 wherein the sugar is present in an amount of from about 10% to about 40% W/V.
9. The composition of Claim 8 which further includes a thickening agent.
10. The pharmaceutical composition of Claim 9 comprising from about 4.0% to about 8.0% of cimetidine, from about 10% to about 40% of mannitol from about 0.1% to about 5.0% of Cab-O-Sil and from about 40% to about 90% of partially hydrogenated soybean oil.
11. The pharmaceutical composition of Claim 1 wherein the histamine H2-antagonist is ranitidine.
EP91917176A 1990-09-13 1991-09-10 Non-aqueous liquid oral suspensions Withdrawn EP0548238A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58186690A 1990-09-13 1990-09-13
US581866 1990-09-13

Publications (1)

Publication Number Publication Date
EP0548238A1 true EP0548238A1 (en) 1993-06-30

Family

ID=24326890

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91917176A Withdrawn EP0548238A1 (en) 1990-09-13 1991-09-10 Non-aqueous liquid oral suspensions

Country Status (7)

Country Link
EP (1) EP0548238A1 (en)
JP (1) JPH06501003A (en)
AU (1) AU8546591A (en)
NZ (1) NZ239784A (en)
PT (1) PT98975A (en)
WO (1) WO1992004893A1 (en)
ZA (1) ZA917310B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3476447A (en) * 1968-03-28 1969-11-04 Westinghouse Electric Corp Self-aligning hydrostatic bearing
MX9306393A (en) * 1992-10-16 1994-04-29 Glaxo Group Ltd RANITIDINE COMPOSITIONS SUBSTANTIALLY FREE OF BITTER TASTE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
US5484800A (en) * 1994-08-30 1996-01-16 American Home Products Corporation Lipid-based liquid medicinal composition
GB9418530D0 (en) * 1994-09-14 1994-11-02 Glaxo Group Ltd Medicaments
AU7468096A (en) * 1995-10-30 1997-05-22 Warner-Lambert Company Enhanced anti-inflammatory oral composition containing h2 receptor antagonist and antimicrobial oils
ES2153786B1 (en) * 1999-06-10 2001-10-16 S A L V A T Lab Sa LIQUID PHARMACEUTICAL COMPOSITION FOR THE ORAL ADMINISTRATION OF AMARGE AND SUSCEPTIBLE ACTIVE HYDROLYSIS PRINCIPLES.
CA2847885C (en) 2001-11-30 2022-03-22 Amgen Fremont Inc. Transgenic animals bearing human ig.lambda. light chain genes
WO2004004682A2 (en) * 2002-07-02 2004-01-15 Laboratorios S.A.L.V.A.T., S.A. Stable oily suspension of microgranules
US20040202696A1 (en) * 2003-04-14 2004-10-14 Cts Chemical Industries Ltd. Administration form for veterinary use
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
CN101610754A (en) 2007-02-16 2009-12-23 Aska制药株式会社 The pharmaceutical composition that contains fine particle oil-based suspension
EP2910571B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
JP2013504610A (en) * 2009-09-16 2013-02-07 ノヴォ ノルディスク アー／エス Stable non-aqueous liquid pharmaceutical composition comprising insulin
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
GB2529605B (en) * 2014-06-03 2018-03-21 Essential Pharmaceuticals Ltd Pharmaceutical composition
BR102015024165A2 (en) * 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda oral pharmaceutical composition comprising cannabinoid, process for its preparation and use
MX2019006463A (en) 2016-12-16 2019-08-14 Novo Nordisk As Insulin containing pharmaceutical compositions.
US11433024B2 (en) 2018-04-27 2022-09-06 Johnson & Johnson Consumer Inc. Liquid oral pharmaceutical dosage form

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0684420B2 (en) * 1986-12-26 1994-10-26 三菱レイヨン株式会社 Active energy ray curable resin composition
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9204893A1 *

Also Published As

Publication number Publication date
PT98975A (en) 1992-07-31
JPH06501003A (en) 1994-01-27
NZ239784A (en) 1994-05-26
AU8546591A (en) 1992-04-15
WO1992004893A1 (en) 1992-04-02
ZA917310B (en) 1992-10-28

Similar Documents

Publication Publication Date Title
EP0548238A1 (en) Non-aqueous liquid oral suspensions
US5059626A (en) Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
US4918103A (en) Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
US6806256B2 (en) Taste masked liquid pharmaceutical compositions
FR2727016A1 (en) ONDANSETRON-BASED PHARMACEUTICAL COMPOSITIONS
FR2727015A1 (en) ONDANSETRON LIQUID PHARMACEUTICAL COMPOSITIONS
EP0043616A2 (en) Edible, pharmaceutical compositions and processes for making thereof
US4259323A (en) Potassium chloride emulsion
US5011852A (en) Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
CA1333773C (en) Antitussive liquid compositions containing phenol
DD238920A5 (en) PROCESS FOR PREPARING AN IMPROVED DAMAGING DEFLECTIVE COMPOSITION
WO2000066170A1 (en) Prucalopride oral solution
US5534552A (en) Clear non-alcoholic sinus and allergy medication
IE913216A1 (en) Non-aqueous liquid oral suspensions
US6235733B1 (en) Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors
US6265449B1 (en) Aqueous compositions comprising ranitidine and LCMT sucrose
US20050136116A1 (en) Stabilized prednisolone sodium phosphate solutions
US20020061884A1 (en) Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors
US20060127472A1 (en) Taste-masked prednisolone oral formulations
JPH0672897A (en) Composition for reducing various unplesant symptoms before and during menstruation
MXPA00007579A (en) Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

17Q First examination report despatched

Effective date: 19950427

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950907